JP7175887B2 - ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法 - Google Patents

ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法 Download PDF

Info

Publication number
JP7175887B2
JP7175887B2 JP2019524067A JP2019524067A JP7175887B2 JP 7175887 B2 JP7175887 B2 JP 7175887B2 JP 2019524067 A JP2019524067 A JP 2019524067A JP 2019524067 A JP2019524067 A JP 2019524067A JP 7175887 B2 JP7175887 B2 JP 7175887B2
Authority
JP
Japan
Prior art keywords
arginine
peptide
amino acids
bicyclic
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019524067A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502051A (ja
JP2020502051A5 (enExample
Inventor
デフア・ペイ
ジーチン・チアン
Original Assignee
オハイオ・ステイト・イノベーション・ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オハイオ・ステイト・イノベーション・ファウンデーション filed Critical オハイオ・ステイト・イノベーション・ファウンデーション
Publication of JP2020502051A publication Critical patent/JP2020502051A/ja
Publication of JP2020502051A5 publication Critical patent/JP2020502051A5/ja
Priority to JP2022179784A priority Critical patent/JP7490735B2/ja
Application granted granted Critical
Publication of JP7175887B2 publication Critical patent/JP7175887B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2019524067A 2016-11-09 2017-11-09 ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法 Active JP7175887B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022179784A JP7490735B2 (ja) 2016-11-09 2022-11-09 ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662419781P 2016-11-09 2016-11-09
US62/419,781 2016-11-09
US201662425550P 2016-11-22 2016-11-22
US62/425,550 2016-11-22
US201662438141P 2016-12-22 2016-12-22
US62/438,141 2016-12-22
PCT/US2017/060881 WO2018089648A2 (en) 2016-11-09 2017-11-09 Di-sulfide containing cell penetrating peptides and methods of making and using thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022179784A Division JP7490735B2 (ja) 2016-11-09 2022-11-09 ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法

Publications (3)

Publication Number Publication Date
JP2020502051A JP2020502051A (ja) 2020-01-23
JP2020502051A5 JP2020502051A5 (enExample) 2020-12-03
JP7175887B2 true JP7175887B2 (ja) 2022-11-21

Family

ID=62109979

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019524067A Active JP7175887B2 (ja) 2016-11-09 2017-11-09 ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法
JP2022179784A Active JP7490735B2 (ja) 2016-11-09 2022-11-09 ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022179784A Active JP7490735B2 (ja) 2016-11-09 2022-11-09 ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法

Country Status (7)

Country Link
US (2) US11351222B2 (enExample)
EP (1) EP3538125A4 (enExample)
JP (2) JP7175887B2 (enExample)
CN (2) CN110114075B (enExample)
CA (1) CA3043464A1 (enExample)
TW (1) TWI781963B (enExample)
WO (1) WO2018089648A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023025022A (ja) * 2016-11-09 2023-02-21 オハイオ・ステイト・イノベーション・ファウンデーション ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018098226A1 (en) 2016-11-22 2018-05-31 Ohio State Innovation Foundation Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha
WO2018098282A2 (en) * 2016-11-22 2018-05-31 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
NZ756012A (en) 2017-01-17 2025-10-31 Michael David Forrest Therapeutic inhibitors of the reverse mode of atp synthase
WO2019012149A1 (en) 2017-07-13 2019-01-17 Forrest Michael David THERAPEUTIC MODULATORS OF THE INVERSE MODE OF ATP SYNTHASE
WO2019070962A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation BICYCLIC PEPTIDE INHIBITORS
CN117567639A (zh) 2017-10-27 2024-02-20 俄亥俄州国家创新基金会 用于细胞内递送装订肽的多肽缀合物
US11793884B2 (en) 2018-01-29 2023-10-24 Ohio State Innovation Foundation Cyclic peptidyl inhibitors of CAL-PDZ binding domain
WO2019148194A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-nfat interaction
EP3790890A4 (en) 2018-05-09 2022-03-02 Ohio State Innovation Foundation CYCLIC PEPTIDES OF CELL PENETRATION WITH ONE OR MORE HYDROPHOBIC RESIDUES
EP3817776A4 (en) 2018-07-02 2022-11-30 Ohio State Innovation Foundation POLYPEPTIDE CONJUGATES FOR INTRACELLULAR RELEASE OF NUCLEIC ACIDS
WO2020019072A1 (en) 2018-07-23 2020-01-30 The Governors Of The University Of Alberta Genetically-encoded bicyclic peptide libraries
JP7611815B2 (ja) * 2019-03-28 2025-01-10 株式会社カネカ 細胞膜透過性環状ペプチド作製用リンカー分子、及びその利用
WO2021102322A1 (en) * 2019-11-21 2021-05-27 Unnatural Products Inc. Cell-permeable cyclic peptides and uses thereof
CN110734474B (zh) * 2019-11-29 2021-10-19 中山大学 一种抗菌肽的筛选方法及其应用
CN115135665A (zh) * 2019-12-30 2022-09-30 俄亥俄州国家创新基金会 包含细胞穿透肽的环状蛋白
WO2022065172A1 (ja) * 2020-09-23 2022-03-31 株式会社カネカ 細胞膜透過性分子及びその利用、並びに細胞膜透過性分子の細胞膜透過性の向上方法
WO2022065173A1 (ja) * 2020-09-23 2022-03-31 株式会社カネカ 細胞膜透過性分子及びその利用、並びに細胞膜透過性分子の細胞膜透過性の向上方法
CA3206148A1 (en) 2021-01-24 2022-07-28 Michael David FORREST Therapeutic modifiers of the reverse mode of atp synthase
EP4358989A4 (en) * 2021-06-22 2025-07-30 Ohio State Innovation Foundation BICYCLIC PEPTIDYL PAN-RAS INHIBITORS

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052875A1 (en) 2000-01-18 2001-07-26 Ludwig Institute For Cancer Research Vegf-d/vegf-c/vegf peptidomimetic inhibitor
US20040014669A1 (en) 2002-04-30 2004-01-22 The Regents Of The University Of California, A California Corporation Antimicrobial theta defensins, analogs thereof, and methods of use
JP2010526091A (ja) 2007-04-30 2010-07-29 インテザイン テクノロジーズ， インコーポレイテッド 癌の処置のための生物学的な標的基の改変
WO2015179691A2 (en) 2014-05-21 2015-11-26 Ohio State Innovation Foundation Cell penetrating peptides and methods of making and using thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804558A (en) 1993-07-20 1998-09-08 University Of California Protegrins
WO2000032235A1 (de) 1998-11-26 2000-06-08 Pentapharm Ag Transportsystemkonjugate
US6864355B1 (en) 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US6960648B2 (en) 2000-10-13 2005-11-01 Universite De Lausanne Intracellular delivery of biological effectors
US7033597B2 (en) 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
WO2007055578A1 (en) 2005-11-11 2007-05-18 Leids Universitair Medisch Centrum Cyclic antimicrobial peptides derived from lactoferrin
AU2006325030B2 (en) 2005-12-16 2012-07-26 Cellectis Cell penetrating peptide conjugates for delivering nucleic acids into cells
US20100221235A1 (en) 2006-02-08 2010-09-02 Diatos Compositions and Methods for Treating Lysosomal Storage Diseases
WO2008017125A1 (en) 2006-08-11 2008-02-14 Starpharma Pty Ltd Targeted polylysine dendrimer therapeutic agent
US7850949B2 (en) * 2006-09-29 2010-12-14 Michigan Technological University Purification of synthetic oligomers
DK2257624T5 (da) 2008-02-05 2012-09-10 Medical Res Council Fremgangsmåder og sammensætninger
WO2010008582A2 (en) 2008-07-18 2010-01-21 Rxi Pharmaceuticals Corporation Phagocytic cell drug delivery system
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
GB201016733D0 (en) 2010-10-05 2010-11-17 Novabiotics Ltd Compounds and their use
RU2556800C2 (ru) 2010-06-14 2015-07-20 Ф.Хоффманн-Ля Рош Аг Пептиды, проникающие в клетки, и их применения
GB201013980D0 (en) 2010-08-20 2010-10-06 Ecole Polytech Bicyclic uPA inhibitors
WO2013036622A2 (en) 2011-09-07 2013-03-14 The Regents Of The University Of California Antiviral peptides effective against hepatitis c virus
WO2014053882A1 (en) 2012-10-04 2014-04-10 Centre National De La Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2014086835A1 (en) 2012-12-05 2014-06-12 Ruprecht-Karls-Universität Heidelberg Conjugates of proteins and multivalent cell-penetrating peptides and their uses
ES2705068T3 (es) 2013-05-23 2019-03-21 Ohio State Innovation Foundation Síntesis química y cribado de bibliotecas de péptidos bicíclicos
US10428115B2 (en) 2013-05-24 2019-10-01 Arizona Board Of Regents On Behalf Of The University Of Arizona Dynorphin A analogs with bradykinin receptors specificity for modulation of neuropathic pain
US20160271216A1 (en) 2013-08-09 2016-09-22 Apellis Pharmaceuticals, Inc. Compositions and methods relating to c5l2
US20160244494A1 (en) 2013-10-01 2016-08-25 President And Fellows Of Harvard College Stabilized polypeptides and uses thereof
AU2014331812B2 (en) * 2013-10-09 2019-01-17 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
US10736932B2 (en) 2014-05-20 2020-08-11 Ohio State Innovation Foundation Small molecule Ras inhibitors
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
WO2016054510A1 (en) 2014-10-02 2016-04-07 Temple University-Of The Commonwealth System Of Higher Education Synthesis of cell penetrating peptides for drug delivery and stem cell applications
EP3184541A1 (en) * 2015-12-23 2017-06-28 Institut Pasteur Stapled peptide inhibitors of nemo as potential anti-inflammatory and anti-cancer drugs
CN110114075B (zh) * 2016-11-09 2024-01-12 俄亥俄州国家创新基金会 含有二硫化物的细胞穿透肽及其制备和使用方法
WO2018098226A1 (en) 2016-11-22 2018-05-31 Ohio State Innovation Foundation Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha
TW202500573A (zh) 2016-11-22 2025-01-01 俄亥俄州立創新基金會 細胞穿透肽序列
WO2018098282A2 (en) 2016-11-22 2018-05-31 Ohio State Innovation Foundation Cyclic cell penetrating peptides comprising beta-hairpin motifs and methods of making and using thereof
WO2019070962A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation BICYCLIC PEPTIDE INHIBITORS
US10738093B2 (en) 2018-01-25 2020-08-11 The Hong Kong University Of Science And Technology Discovery of cationic nonribosomal peptides as Gram-negative antibiotics through global genome mining
WO2019148194A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-nfat interaction

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001052875A1 (en) 2000-01-18 2001-07-26 Ludwig Institute For Cancer Research Vegf-d/vegf-c/vegf peptidomimetic inhibitor
US20040014669A1 (en) 2002-04-30 2004-01-22 The Regents Of The University Of California, A California Corporation Antimicrobial theta defensins, analogs thereof, and methods of use
JP2010526091A (ja) 2007-04-30 2010-07-29 インテザイン テクノロジーズ， インコーポレイテッド 癌の処置のための生物学的な標的基の改変
WO2015179691A2 (en) 2014-05-21 2015-11-26 Ohio State Innovation Foundation Cell penetrating peptides and methods of making and using thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023025022A (ja) * 2016-11-09 2023-02-21 オハイオ・ステイト・イノベーション・ファウンデーション ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法
JP7490735B2 (ja) 2016-11-09 2024-05-27 オハイオ・ステイト・イノベーション・ファウンデーション ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法

Also Published As

Publication number Publication date
TWI781963B (zh) 2022-11-01
CN117866042A (zh) 2024-04-12
CN110114075B (zh) 2024-01-12
US11351222B2 (en) 2022-06-07
US20220160819A1 (en) 2022-05-26
US20190282654A1 (en) 2019-09-19
JP2020502051A (ja) 2020-01-23
CN110114075A (zh) 2019-08-09
JP7490735B2 (ja) 2024-05-27
EP3538125A2 (en) 2019-09-18
EP3538125A4 (en) 2020-10-07
WO2018089648A3 (en) 2018-06-21
TW201823266A (zh) 2018-07-01
WO2018089648A2 (en) 2018-05-17
US11878046B2 (en) 2024-01-23
JP2023025022A (ja) 2023-02-21
CA3043464A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
JP7490735B2 (ja) ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法
US10501496B2 (en) Chemical synthesis and screening of bicyclic peptide libraries
CN106852146B (zh) 细胞穿透肽及其制备和使用方法
TWI853790B (zh) 細胞穿透肽序列
US20240368224A1 (en) Bicyclic peptidyl pan-ras inhibitors
US11987647B2 (en) Cyclic cell-penetrating peptides with one or more hydrophobic residues
CN111447941B (zh) 用于细胞内递送装订肽的多肽缀合物
WO2018098226A1 (en) Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha
US20190309020A1 (en) Cell-penetrating peptide sequences
EP4294820A1 (en) Cyclic cell-penetrating peptides with three or more hydrophobic residues
CN119136833A (zh) 膜易位结构域及其用途
WO2024026141A2 (en) Cyclic cell-penetrating peptides and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220809

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221011

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221109

R150 Certificate of patent or registration of utility model

Ref document number: 7175887

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250